Methotrexate: first-line or second-line immunomodulator?

被引：50

作者：

Fraser, AG ^{[1
]}

机构：

[1] Univ Auckland, Auckland 1, New Zealand

来源：

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY | 2003年 / 15卷 / 03期

关键词：

methotrexate; Crohn's disease; ulcerative colitis; rheumatoid arthritis;

D O I：

10.1097/00042737-200303000-00003

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

Methotrexate is established as an effective treatment for inducing remission or preventing relapse in Crohn's disease. This review discusses the mechanisms of action, pharmacokinetics and clinical trials as well as considering the comparative efficacy between thiopurines and methotrexate. Comparisons are made with the treatment of rheumatoid arthritis. Its role in ulcerative colitis and potential toxicity are addressed. At present, the role of methotrexate is in the treatment of active or relapsing Crohn's disease for patients who are refractory to, or intolerant of, azathioprine or 6-mercaptopurine.

引用

页码：225 / 231

页数：7

共 71 条

[1]

ALAWADHI A, 1993, J RHEUMATOL, V20, P1121

[2]

Alvarez F, 1996, GASTROENTEROLOGY, V110, pA853

[3]

Ardizzone S, 1999, GASTROENTEROLOGY, V116, pA662

[4]

ARNOLD MH, 1990, BRIT J RHEUMATOL, V29, P120